 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- ||| rilpivirine oral suspension (SACT-1) / Aptorum Group
#SACT-2 Dates are out now : 29-30th September 2023 Register now : https://t.co/YXYcCZTcNC Want to know what to expect ? Have a look at the Glimpses of 1st Inaugural event SACT-1, attended by more than 200+ delegates from Academia & Industry @CTCTC_tmc @DrGauravNarula https://t.co/qZeZjpbZwv (Twitter) - Jul 25, 2023
- || NLS-1 / Aptorum Group, Grupo Insud
PK/PD data, Preclinical, Journal: Determination of (-)-epigallocatechin-3-gallate octaacetate and its metabolites in plasma of rats for pharmacokinetic study by ultra-performance-liquid-chromatography coupled to quadrupole-time-of-flight-mass-spectrometry. (Pubmed Central) - Oct 29, 2022
The pharmacokinetic profiles of pro-EGCG metabolites, (-)-epigallocatechin-gallate (EGCG) diacetates and EGCG triacetates, were also presented. This method is robust, rapid, and sensitive for the pharmacokinetic study of pro-EGCG and metabolites.
- || Edurant (rilpivirine) / J&J, rilpivirine oral suspension (SACT-1) / Aptorum Group
New P1 trial: A Study of Bioavailability and Food Effect of SACT-1 and Edurant (clinicaltrials.gov) - May 2, 2022
P1, N=16, Completed, Sponsor: Aptorum International Limited
- | ALS-4 / Aptorum Group
New P1 trial: A Study of ALS-4 in Healthy Adults Subjects (clinicaltrials.gov) - Mar 9, 2022
P1, N=72, Completed, Sponsor: Aptorum International Limited
- SACT-1 / Aptorum Group
[VIRTUAL] Aptorum Group Limited () - May 31, 2021 - Abstract #BIO2021BIO_240;
In particular, Aptorum Group is currently developing therapeutics in the areas of oncology, infectious diseases and women’s health. Targeted development milestones for some of the key programs include: ALS-4 (next-generation anti-infective for Staphylococcus aureus including MRSA via a non-bactericidal antivirulent approach): a new chemical entity (NCE) small molecule drug currently in a Phase 1 clinical trial, targeted for potential administration both on a standalone or a combined basis with other existing antibiotics such as vancomycin; SACT-1 (neuroblastoma & other solid tumours): a repurposed drug programme with prior human safety and toxicity data available, in preparation to open an IND with US FDA to commence clinical studies in 2021; (cont.)